Newsletter | May 6, 2024

05.06.24 -- Considerations For Direct-To-Patient Offerings

SPONSOR

Webinar: Jumpstart Your QMSR Transition: Get Ahead of Evolving Regulations

Save the date for May 16th! During this Cell & Gene webinar, Kymanox experts in Quality and Regulatory Affairs will guide you through your transition to the QMSR, while discussing key changes and impact from new requirements, and ensuring that your company achieves compliance by the February 2026 effective date. Click here to learn more.

FEATURED ARTICLE

Building On Direct-To-Patient Marketing For Improved Access To Therapeutics

PA Consulting identifies the top three questions that biopharmaceutical companies should consider before launching a direct-to-patient platform and service offering.

INDUSTRY INSIGHTS

Adherent Versus Suspension Processes For Viral Vector Manufacturing

In adherent cell culture, cells are grown while attached to a substrate as monolayers. In suspension cell culture, cells are free-floating in the culture medium. Which offers more benefits?

Breaking Barriers In Heterodimer Formation: S-KiH Platform Technology

Market demand for bispecific antibody-based therapies (BsAbs) is growing rapidly due to the wide range of applications for these molecules in research and diagnostics.

Ophthalmic Drug Delivery

Explore the challenges to effective delivery of drugs to the eye, the intricacies of ophthalmic drug delivery, and the advantages of nanoparticles as an enabling technology for ocular systems.

Developing Biosimilars: Challenges And Solutions

The technologies used for biophysical characterization often require expensive reagents, large sample quantities, and optimization for experimental conditions. Simplified analytical workflows can help.

What It Really Takes To Adopt eConsent Across Large Pharma

Find the benefits of incorporating consent management technology, and discover practical strategies for developing effective change management and training programs.

Harnessing mRNA As A Readout To Develop Robust BioPotency Assays

Discover a new potency bioassay using RT-qPCR to assess relative transcription activity, and learn more about the advantages and limitations of transcriptional assays versus reporter gene assays.

SPONSOR

The Future of Biotechnology in Individualized Medicine conference will explore the ongoing evolution of genomics from a tool for diagnostic breakthroughs to a driver of revolutionary therapeutics. Organized jointly by the Scripps Research Translational Institute, Actio Biosciences, and Advancing Precision Medicine, attendees will hear from renowned leaders from across academia and industry speak on the most recent innovation and trends in genomic medicine. View the full agenda and register here.

CONTRIBUTE TO LIFE SCIENCE LEADER

Article Submission Guidelines Life Science Leader

Think you have a good idea for an article that Life Science Leader readers would find valuable?  Read these guidelines first before submitting your idea or your article to our editorial director. 

Connect With Life Science Leader: